Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA UCSD
Dates
study started
completion around
Principal Investigator
by Gottfried E. Konecny, MD (ucla)
Headshot of Gottfried E. Konecny
Gottfried E. Konecny

Description

Summary

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.

Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Official Title

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

Details

Keywords

High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, antibody-drug conjugate, folate receptor alpha, folate receptor, solid tumor, ovarian cancer, breast cancer, hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer, topoisomerase I inhibitor, PROC, epidermal growth factor receptor (EGFR)-mutated NSCLC, Breast Neoplasms, Lung Neoplasms, Non-Small-Cell Lung Carcinoma, Ovarian Neoplasms, Ovarian Epithelial Carcinoma, Endometrial Neoplasms, Triple Negative Breast Neoplasms, Malignant Mesothelioma, Fallopian Tube Neoplasms, Uterine Neoplasms, Bevacizumab, Pembrolizumab, Carboplatin, Rina-S

Eligibility

Locations

  • University of California Los Angeles Medical Center accepting new patients
    Los Angeles California 90095 United States
  • University of California, San Diego; Moores Cancer Center accepting new patients
    San Diego California 92093 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Genmab
ID
NCT05579366
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 529 study participants
Last Updated